|
Genzyme Responds to Sanofi-Aventis Letter
|
08 November 2010 |
|
Genzyme Reports Financial Results for the Third Quarter of 2010
|
21 October 2010 |
|
Genzyme Announces Results of Phase 3 Trial of Clolar
|
21 October 2010 |
|
Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability
|
15 October 2010 |
|
Genzyme Board Unanimously Rejects Sanofi-Aventis Tender Offer
|
08 October 2010 |
|
Genzyme Board Urges Shareholders to Take No Action on sanofi-aventis' Unsolicited Tender Offer
|
05 October 2010 |
|
Genzyme Announces Agreement to Sell Genetic Testing Business to LabCorp
|
13 September 2010 |
|
Genzyme Confirms Receipt of Unsolicited Proposal
|
30 August 2010 |
|
Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
|
05 August 2010 |
|
Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
|
15 June 2010 |
|
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
|
26 May 2010 |
|
Additional Alemtuzumab Mechanism of Action Data Reported
|
15 April 2010 |
|
Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
|
18 February 2010 |
|
Genzyme Reports Fourth-Quarter Revenue
|
13 January 2010 |
|
Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population
|
18 November 2009 |
|
Genzyme Delivers Solid Second-Quarter Financial Results
|
23 July 2009 |
|
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
|
15 June 2009 |
|
Genzyme Completes Transaction with Bayer HealthCare
|
03 June 2009 |
|
Genzyme to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare
|
07 April 2009 |
|
Genzyme and Isis Begin New Clinical Trials of Mipomersen
|
13 January 2009 |